Bayer announces that results from a Phase II study show that simultaneous initiation of finerenone (Kerendia) and empagliflozin (SGLT-2 inhibitor) resulted ina significant reduction in albuminuria (UACR) in adults with chronic kidney disease (CKD) associated with type 2 diabetes.

This reduction reached 52% at 180 days, compared with 29% and 32% with monotherapies, respectively.Presented at the European Renal Association 2025 congress and published in the New England Journal of Medicine, the study also shows that approximately 75% of patients achieved a reduction in UACR greater than 30% within the first two weeks.

This dual therapy demonstrated a good safety profile and tolerability.30% within the first two weeks. This dual therapy showed a good tolerance profile and consistent efficacy in all subgroups studied, the laboratory emphasizes.Bayer emphasizes that this combination strategy could significantly improve the management of millions of patients with MDR associated with type 2 diabetes.


Copyright (c) 2025 CercleFinance.com. All rights reserved.